Madrid, September 25th 2014.– Santiago de Compostela was the venue to numerous participants from national and international pharmaceutical companies, Spanish biotech companies and research groups, on the occasion of the celebration of the XII Pharma-Biotech Cooperation Meeting, a reference in biotechnology cooperation, organized by FARMAINDUSTRIA. This meeting, held in the context of the BioSpain 2014 fair, has now -for the 12th time- been fostering and stimulating the cooperation between these similar kinds of companies and institutions in the biotechnology field, which is the reason why it has become such a true reference.

As its main objective, the initiative is that Spanish companies and research groups from specialized centers, which were previously selected, present and exhibit their products in development to the audience, which is constituted –mainly- by pharma-ceutical companies with a previous interest in this topic. These work in progress products entail sufficient potential (not only because of their innovative character, but also for being effective and protected), to become a real opportunity of cooperation to be capitalized by both parts.

During this years’ edition, presentations were given by Bionure, IDIS, Spherium Biomed, Oncomatrix, Ankar Farma, NeuronBio, Life Length, Hospital Virgen del Rocio, University of Vigo and CIMA. Said presentations focused around the business opportunity aspects of each new product in advanced development, by taking into account the differential traits, therapeutic action range, global market expectations and the degree of already passed tests, both clinical and preclinical.

A year on, and this meeting has been acknowledged by both pharmaceutical companies as well as by companies and participating groups, the Farma-Biotech cooperation meeting represented an unbeatable framework for interactions between all parts, allows each of them to identify the added value arising from the information interchanged between demand and supply, always from the new therapies and advanced medicines perspective.

As a matter of fact, these meetings have already brought about the signature of three transfer agreements, thus becoming the cannel for affiliates of multinational companies based in Spain to convey their Centre’s decision making on biotechnological products, in turn, providing for further meetings and visits to said centers in Spain. Javier Urzay, FARMAINDUSTRIA’s Deputy Director, who gave the opening speech at the meeting said, “with this Program, we pursue to contribute to the transfer of value and technology from the paradigm of open innovation, with the ultimate aim of improving the access of innovative medicines to patients”.